$DRMA Cashflow Statement | Understand Stock

$DRMA

$0.87 +$0.12 (15.85%) Close

$DRMA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Amortization of debt discount costs
Depreciation of fixed assets
Gain from forgiveness of Paycheck Protection Plan loan
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets
Accounts payable

Accrued and other current liabilities
License and settlement agreement
Total adjustments to reconcile net loss to net cash used in operations
Total adjustments to reconcile net loss to cash used in operations
Accrued and other current liabilities
Net cash used in operating activities
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants, net of issuance costs
Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs
Proceeds from issuances of common stock upon exercises of pre-funded warrants
Redemption of Series 1c preferred stock
Payments on debt
Proceeds from Paycheck Protection Plan loan
Proceeds from issuance of Series 1c preferred units
Proceeds from exercise of Series 1a preferred warrant units
Net proceeds from issuance of convertible subordinated promissory notes
Proceeds from issuance of Series 1d preferred units
Payment of prior period issuance costs
Proceeds from exercise of pre-funded warrants
Payment for fractional shares in reverse stock split
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash at end of period
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure:
Cash paid for interest
Cash paid for taxes

Non-cash financing activities:
Conversion of common and preferred units and warrants to common and preferred stock and warrants
Conversion of convertible subordinated promissory notes to Series 1d preferred units
Deemed dividend upon amendment to the terms to the Series 1d convertible preferred stock
Deemed dividend upon amendment to the terms of the Series 1d convertible preferred stock
Conversion of convertible subordinated promissory notes and accrued interest to common shares at IPO
Conversion of preferred stock to common stock at IPO
Incremental fair value of March 2023 warrant modification
Incremental fair value of November 2023 warrant inducement
Incremental fair value of May 2024 warrant inducement
Issuance costs in accounts payable
Issuance of abeyance shares
Issuance costs in accounts payable or accrued expenses

Comments